Drug interactions in nutrition support

Handbook of Food-Drug Interactions

Volumn , Issue , 2003, Pages 145-166

  Strausburg, Kathleen M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746917873     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. ASPEN, Board of Directors, Standards of practice: definition of terms used in ASPEN guidelines and standards, Nutr. Clin. Pract.,10, 1-3, 1995.
2. ASPEN, Board of Directors and the Clinical Guidelines Taskforce, Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients, J. Parental Enteral Nutr.,26, 185A-215A, 2002.
3. Strausburg, K.M., Parenteral nutrition admixture, in The A.S.P.E.N. Nutrition Support Manual, Souba, W.W. et al., Eds., A.S.P.E.N., Kansas City, MO, 8-1-8-12, 1998.
4. Olree, K. et al., Enteral formulations, in The A.S.P.E.N. Nutrition Support Manual, Souba, W.W. et al., Eds. A.S.P.E.N., Kansas City, MO, 4-1-4-9, 1998.
5. Schneider, PJ. and Mirtallo, J.M., Medication profiles in TPN patients, Nutr. Suppl. Serv.,3, 40-48, 1983.
6. Driscoll, D.F., Drug-induced metabolic disorders and parenteral nutrition in the intensive care unit: a pharmaceutical and metabolic perspective, DICP, Ann. Pharmaco-ther.,23, 363-371, 1989.
7. Cerulli, J. and Malone, M., Assessment of drug-related problems in clinical nutrition patients, J. Parental Enteral Nutr.,23, 218-221, 1999.
8. Hatton, J., Pharmacotherapy and nutrition, in Pharmacotherapy Self-Assessment Program, Module 8 Gastroenterology Nutrition,3rd ed., Carter, B.L. et al., Eds., American College of Clinical Pharmacy, Kansas City, MO, 1999, pp. 157-183.
9. Rosmarin, D.K., Wardlaw, G.M., and Mirtallo, J., Hyperglycemia associated with high, continuous infusion rates of total parenteral nutrition, Nutr. Clin. Pract.,11, 151-156, 1996.
10. Teasley-Strausburg, K.M., Metabolic and gastrointestinal complications, in Nutrition Support Handbook—A Compendium of Products with Guidelines for Usage, Teasley-Strausburg, K.M., Ed., Harvey Whitney Books Company, Cincinnati, OH, 1992, pp. 295-303.
11. Klang, M.G., Hayes, E.M., and Bloss, C.S., Drug-nutrient considerations—parenteral nutrition, in The A.S.P.E.N. Nutrition Support Manual, Souba, W.W. et al., Eds., A.S.P.E.N., Kansas City, MO, 10-1-10-11, 1998.
12. Brown, R.O. and Dickerson, R.N., Drug-nutrient interactions, Am. J. Managed Care, 5, 345-352, 1999.
13. Pandit, M.K. et al., Drug-induced disorders of glucose tolerance, Ann. Intern. Med., 118, 529-539, 1993.
14. Seagraves, A. et al., Net protein catabolic rate after kidney transplantation: impact of corticosteroid immunosuppression, J. Parental Enteral Nutr.,10, 453-455, 1986.
15. Magnuson, B. et al., Tolerance and efficacy of enteral nutrition neurosurgical patients in pentobarbital coma, Nutr. Clin. Pract.,14, 131-134, 1999.
16. Seidner, D.L. and Speerhas, R., Yes, Octreotide can be added to parenteral nutrition solutions, Nutr. Clin. Pract.,13, 84-87, 1998.
17. Lamberts, S.W.J. et al., Octreotide, N. Engl. J. Med.,334, 246-254, 1996.
18. Sentipal-Walerius, J. et al., Effect of pulsed dexamethasone therapy on tolerance of intravenously administered lipids in extremely low birth weight infants, J. Pediatr., 134, 229-232, 1999.
19. Lowrey, T.S. et al., Pharmacologic influence on nutrition support therapy: use of propofol in a patient receiving combined enteral and parenteral nutrition support, Nutr. Clin. Pract.,11, 147-149, 1996.
20. Greenblatt, S.H. et al., Catabolic effect of dexamethasone in patients with major head injury, J. Parental Enteral Nutr.,13, 372-376, 1989.
21. Teasley-Strausburg, K.M. and Anderson, J.D., Assessment of nutrition status and nutrition requirements, in Pharmacotherapy—A Pathophysiologic Approach,4th ed., DiPiro, J.T. et al., Eds., Appleton-Lange, Stamford, CT, 1999, pp. 2221-2236.
22. Lacy, C.F. et al., Eds., Drug Information Handbook,7th ed., Lexi-Comp, Cleveland, 1999.
23. Fernandez, L.A. et al., The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation, Transplantation,68, 1532-1541, 1999.
24. Carreras, E. et al., Hypertriglyceridemia in bone marrow transplant recipients: another side effect of cyclosporine A, Bone Marrow Transpl.,4, 385-388, 1989.
25. Dresner, L.S. et al., Effects of cyclosporine on glucose metabolism, Surgery,106, 163-169, 1989.
26. Dickerson, R.N. et al., Pentobarbital improves nitrogen retention in sepsis, J. Parental Enteral Nutr.,13, 359-361, 1989.
27. Sacks, G.S. and Brown, R.O., Drug-nutrient interactions in patients receiving nutritional support, Drug Ther., March 25, 1994, 41.
28. Roth, M.S., Martin, A.B., and Katz, J.A., Nutritional implications of prolonged propofol use, Am. J. Health Syst. Pharm.,54, 694-695, 1997.
29. Solomon, S.M. and Kirby, D.F., The refeeding syndrome: a review, J. Parental Enteral Nutr.,14, 90-97, 1990.
30. Miller, J.S. and Simpson, J., Medication-nutrient interactions: hypophosphatemia associated with sucralfate in the intensive care unit, Nutr. Clin. Pract.,6, 199-201, 1991.
31. Brady, J.A., Rock, C.L., and Horneffer, M.R., Thiamin status, diuretic medications, and the management of congestive heart failure, J. Am. Diet. Assoc.,95, 541-544, 1995.
32. Marcuard, S.P., Albernaz, L., and Khazanie, P.G., Omeprazole therapy causes malabsorption of cyanocobalamin, Ann. Intern. Med.,120, 211-215, 1994.
33. National Advisory Group on Standards and Practice Guidelines for Parenteral Nutrition, Safe practices for parenteral nutrition formulations, J. Parental Enteral Nutr., 22, 49-66, 1998.
34. Trissel, L.A., Handbook on Injectable Drugs,12th ed., American Society of Health-System Pharmacists, Bethesda, MD, 2002.
35. King, J.C. and Catania, P.N., ed., King Guide to Parenteral Admixtures, King Guide Publications, Inc., Napa, CA, 2002.
36. Trissel, L.A., Gilbert, D.L., and Martinez, J.F., Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration, Am. J. Health Syst. Pharm.,54, 1295-1300, 1997.
37. Trissel, L.A. et al., Compatibility of medications with 3-in-1 parenteral nutrition admixtures, J. Parental Enteral Nutr.,23, 67-74, 1999.
38. Moshfeghi, M. and Ciuffo, J.D., Visual compatibility of fentanyl citrate with parenteral nutrient solutions, Am. J. Health Syst. Pharm.,55, 1194-1197, 1998.
39. Nyffeler, M.S., Ciprofloxacin use in the enterally fed patient, Nutr. Clin. Pract.,14, 73-77, 1999.
40. Wright, D.H. et al., Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation, J. Parental Enteral Nutr.,24, 42-48, 2000.
41. Healy, D.P., Brodbeck, M.C., and Dlendening, C.E., Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunos-tomy tubes, Antimicrob. Agents Chemother.,40, 6-10, 1996.
42. Bauer, L.A., Interference of oral phenytoin absorption by continuous nasogastric feedings, Neurology,32, 570-572, 1982.
43. Yeung, A. and Ensom, M.H., Phenytoin and enteral feedings: does evidence support an interaction?Ann. Pharmacother.,34, 896-905, 2000.
44. Fleisher, D., Sheth, N., and Kou, J.H., Phenytoin interaction with enteral feedings administered through nasogastric tubes, J. Parental Enteral Nutr.,14, 513-516, 1990.
45. Rodman, D.P., Stevenson, T.L., and Ray, T.R., Phenytoin malabsorption after jejun-ostomy tube delivery, Pharmacotherapy,15, 801-805, 1995.
46. Doak, K.K. et al., Bioavailability of phenytoin acid and phenytoin sodium with enteral feeding, Pharmacotherapy,18, 637-645, 1998.
47. Johnson, D.R. and Nyffeler, M.S., Drug-nutrient considerations for enteral nutrition, in The A.S.P.E.N. Nutrition Support Manual, Souba, W.W. et al., Eds., A.S.P.E.N., Kansas City, MO, 1998, 6-1-6-20.
48. Beckwith, M.C., Barton, R.G., and Graves, C., A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods, Hospital Pharm.,32, 57-64, 1997.
49. Gora, M.L., Tschampel, M.M., and Visconti, J.A., Considerations of drug therapy in patients receiving enteral nutrition, Nutr. Clin. Pract.,4, 105-110, 1989.
50. Dunn, A. et al., Delivery of omeprazole and lansoprazole granules through a nasogastric tubein vitro, Am. J. Health Syst. Pharm.,56, 2327-2330, 1999.
51. Lehmann, S., Medication administration via feeding tubes, in Nutrition Support Handbook—A Compendium of Products with Guidelines for Usage, Teasley-Straus-burg, K.M., ed., Harvey Whitney Book Company, Cincinnati, OH, 1992, 305-320.
52. Mitchell, J.F., Oral dosage forms that should not be crushed: 2000 update, Hosp. Pharm.,35, 553-567, 2000.
53. Quercia, R.A. et al., Stability of omeprazole in an extemporaneously prepared liquid, Am. J. Health Syst. Pharm.,54, 1833-1836, 1997.
54. Phillips, J.O., Metzler, M.H., and Olsen, K., The stability of simplified lansoprazole suspension (SLS), Gastroenterology,116, A89, 1999.
55. Cleary, J.D. et al., Administration of crushed extended-release pentoxifylline tablets: bioavailability and adverse effects, Am. J. Health Syst. Pharm.,56, 1529-1534, 1999.
56. Cutie, A.J., Altman, E., and Lenkel, L., Compatibility of enteral products with commonly employed drug additives, J. Parental Enteral Nutr.,7, 186-191, 1983.
57. Holtz, L., Milton, J., and Sturek, J.K., Compatibility of medications with enteral feedings, J. Parental Enteral Nutr.,11, 183-186, 1987.
58. Strom, J.G. and Miller, S.W., Stability of drugs with enteral nutrient formulas, DICP, Ann. Pharmacother.,24, 130-134, 1990.
59. Udeani, G.O., Bass, J., and Johnston, T.P., Compatibility of oral morphine sulfate solution with enteral feeding products, Ann. Pharmacother.,28, 451-455, 1994.
60. Crowther, R.S., Bellanger, R., and Szauter, K.E.M., In vitro stability of ranitidine hydrochloride in enteral nutrient formulas, Ann. Pharmacother.,29, 859-862, 1995.
61. Bussy, V., Marechal, F., and Nasca, S., Microbial contamination of enteral feeding tubes occurring during nutritional treatment, J. Parental Enteral Nutr.,16, 552-557, 1992.
62. Anderson, K.R. et al., Bacterial contamination of tube-feeding formulas, J. Parental Enteral Nutr.,8, 673-678, 1984.
63. Levy, J. et al., Contaminated enteral nutrition solutions as a cause of nosocomial bloodstream infections: a study using plasmid finger printing, J. Parental Enteral Nutr.,13, 228-234, 1989.
64. Navajas, M. et al., Bacterial contamination of enteral feeds as a possible risk of nosocomial infection, J. Hosp. Infect.,21, 111-121, 1992.
65. Engle, K.K. and Hannawa, T.E., Techniques for administering oral medications to critical care patients receiving continuous enteral nutrition, Am. J. Health Syst. Pharm.,56, 1441-1444, 1999.
66. Bowling, T.E. and Silk, D.B.A., Diarrhea and enteral nutrition, in Clinical Nutrition—Enteral and Tube Feeding, Rombeau, J.L. and Rolandelli, R.H., Eds., W.B. Saunders Co., Philadelphia, 1997, pp. 540-553.
67. Guenter, P.A. et al., Tube feeding-related diarrhea in acutely ill patients, J. Parental Enteral Nutr.,15, 277-280, 1991.
68. Fuhrman, P.M., Diarrhea and tube feeding, Nutr. Clin. Pract.,14, 83-84, 1999.
69. Williams, M.S. et al., Diarrhea management in enterally fed patients, Nutr. Clin. Pract.,13, 225-229, 1998.
70. Guenter, P.A. et al., Tube feeding-related diarrhea in acutely ill patients, J. Parental Enteral Nutr.,15, 277-280, 1991.
71. Edes, T.F., Walk, B.E., and Austin, J.L., Diarrhea in tube-fed patients: feeding formula not necessarily the cause, Am. J. Med.,88, 91-93, 1990.
72. Miller, S.J. and Oliver, A.D., Sorbitol content of selected sugar-free liquid medications, Hosp. Pharm.,28, 741-744, 1993.
73. Lutomski, D.M. et al., Sorbitol content of selected oral liquids, Ann. Pharmacother., 27, 269-274, 1993.
74. Thomson, C.A. and Rollins, C.J., Nutrient-drug interactions, in Clinical Nutrition, Enteral and Tube Feeding,3rd ed., Rombeau, J.L. and Rolandelli, R.H., Eds., W.B. Saunders Co., Philadelphia, 1997, pp. 523-539.
75. Hamaoui, E. and Kodsi, R., Complications of enteral feeding and their prevention, in, Clinical Nutrition—Enteral and Tube Feeding,3rd ed., Rombeau, J.L. and Rolandelli, R.H., Eds., W.B. Saunders Co., Philadelphia, 1997, 554-574.
76. Brandt, N., Medications and dysphagia: how do they impact each other?, Nutr. Clin. Pract.,14, 527-530, 1999.